The increase in the risk of suffering from skin cancer is a strong reason to continue to strengthen existing treatments and look for new alternatives.
Comercializadora de Servicios Médicos Cubanos, S.A. offers integral oncology treatment to people with skin cancer, based on the experience and high scientific preparation of the professionals of the National Institute of Oncology and Radiobiology.
The treatment includes the use of HeberFERON®, a Cuban drug developed by the Center for Genetic Engineering and Biotechnology - with more than 20 years of research and clinical trials - which consists of the synergic combination of recombinant human alpha and gamma Immunoferon. It is indicated for the treatment of basal cell carcinomas, in lesions of any size and location, including high-risk areas, the H-zone of the face, or those locally advanced and difficult to treat due to their proximity to the eyes or the brain.
The treatment provided by the specialists is adjusted to the characteristics of the cancer presented by each patient.
Among its greatest advantages is the fact that it heals the lesions and reduces the tumor mass, provokes a faster therapeutic response, extends the response to treatment for at least five years, reduces the frequency of new lesions by eight times, avoids complex surgeries in the area around the eyes and their after-effects, and generally improves the patient's quality of life.
In the Cuban oncology services that offer this program, the patient is evaluated by multidisciplinary teams (nationally certified and internationally endorsed) made up of internists, radiologists, pathologists, hematologists, surgeons, among others, presided over by a clinical oncologist. These specialists are responsible for establishing, according to the diagnosis and stage of the cancer, the personalized treatment. The amount of product to be used will depend on the area of extension of the lesion.
To begin treatment, you should contact the Coordination and Processing Center of Comercializadora de Servicios Médicos Cubanos, S.A. at smc@smcsalud.cu. You will be sent the medical program with its costs.
Comercializadora de Servicios Médicos Cubanos, S.A. offers integral oncology treatment to people with skin cancer, based on the experience and high scientific preparation of the professionals of the National Institute of Oncology and Radiobiology.
The treatment includes the use of HeberFERON®, a Cuban drug developed by the Center for Genetic Engineering and Biotechnology - with more than 20 years of research and clinical trials - which consists of the synergic combination of recombinant human alpha and gamma Immunoferon. It is indicated for the treatment of basal cell carcinomas, in lesions of any size and location, including high-risk areas, the H-zone of the face, or those locally advanced and difficult to treat due to their proximity to the eyes or the brain.
The treatment provided by the specialists is adjusted to the characteristics of the cancer presented by each patient.
Among its greatest advantages is the fact that it heals the lesions and reduces the tumor mass, provokes a faster therapeutic response, extends the response to treatment for at least five years, reduces the frequency of new lesions by eight times, avoids complex surgeries in the area around the eyes and their after-effects, and generally improves the patient's quality of life.
In the Cuban oncology services that offer this program, the patient is evaluated by multidisciplinary teams (nationally certified and internationally endorsed) made up of internists, radiologists, pathologists, hematologists, surgeons, among others, presided over by a clinical oncologist. These specialists are responsible for establishing, according to the diagnosis and stage of the cancer, the personalized treatment. The amount of product to be used will depend on the area of extension of the lesion.
To begin treatment, you should contact the Coordination and Processing Center of Comercializadora de Servicios Médicos Cubanos, S.A. at smc@smcsalud.cu. You will be sent the medical program with its costs.